Analysis of Subcutaneous (SQ) Alemtuzumab Induction Therapy in Highly Sensitized Patients Desensitized With IVIG and Rituximab

This publication has 14 references indexed in Scilit:

• Banff ’05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (’CAN’)
  American Journal of Transplantation, 2007
• Transplantation of the highly human leukocyte antigen–sensitized patient: long-term outcomes and future directions
  Transplantation Reviews, 2006
• Presensitization
  Clinical Journal of the American Society of Nephrology, 2006
• Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients
  American Journal of Transplantation, 2006
• Antibody-mediated organ-allograft rejection
  Nature Reviews Immunology, 2005
• Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation―Efficacy and Safety at Five Years
  American Journal of Transplantation, 2005
• Evaluation of Intravenous Immunoglobulin as an Agent to Lower Allosensitization and Improve Transplantation in Highly Sensitized Adult Patients with End-Stage Renal Disease
  Journal of the American Society of Nephrology, 2004
• Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
  Blood, 2004
• National Conference to Assess Antibody-Mediated Rejection in Solid Organ Transplantation
  American Journal of Transplantation, 2004
• Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
  Leukemia, 2004